Inhibition of Tau filament formation by conformational modulation

Antiaggregation drugs play an important role in therapeutic approaches for Alzheimer’s disease. Although a large number of small molecules that inhibit the aggregation of the tau protein have been identified, little is known about their mode of action. Here, we reveal the mechanism and the nature of...

Full description

Saved in:
Bibliographic Details
Main Author: Akoury, Elias (author)
Other Authors: Gajdat, Michal (author), Pickhardt, Marcus (author)
Format: article
Published: 2013
Online Access:http://hdl.handle.net/10725/10251
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php
https://pubs.acs.org/doi/abs/10.1021/ja312471h
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antiaggregation drugs play an important role in therapeutic approaches for Alzheimer’s disease. Although a large number of small molecules that inhibit the aggregation of the tau protein have been identified, little is known about their mode of action. Here, we reveal the mechanism and the nature of tau species that are generated by interaction of tau with the organic compound pthalocyanine tetrasulfonate (PcTS). We demonstrate that PcTS interferes with tau filament formation by targeting the protein into soluble oligomers. A combination of NMR spectroscopy, electron paramagnetic resonance, and small-angle X-ray scattering reveals that the soluble tau oligomers contain a dynamic, noncooperatively stabilized core with a diameter of 30–40 nm that is distinct from the core of tau filaments. Our results suggest that specific modulation of the conformation of tau is a viable strategy for reduction of pathogenic tau deposits.